Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.49 |
| ▸ | ATP4A | P20648 | 1/20 | 0.41 |
| ▸ | ATP4B | P51164 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782661 | 0.88 | HTR7 (0.55) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2779637 | 0.88 | ATP4A (0.43) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2782840 | 0.87 | CLK2 (0.40) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2779421 | 0.85 | GRIN2B (0.47) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2779645 | 0.84 | ATP4A (0.38) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2778561 | 0.83 | CLK4 (0.48) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2780786 | 0.83 | ATP4A (0.37) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2780709 | 0.83 | ATP4A (0.37) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2782658 | 0.82 | NR3C2 (0.54) | CLK2GSK3AGSK3BCDK9CDK5 | |
| SCHEMBL2780813 | 0.81 | CLK2 (0.49) | CLK2GSK3AGSK3BCDK9CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | claimed |
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1917244-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022964-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | CLK2 3235/4885GSK3A 1010/4885GSK3B 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.